Alunbrig™ (brigatinib) – New orphan drug approval
April 28, 2017 – The FDA announced the approval of Ariad’s Alunbrig (brigatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Xalkori® (crizotinib).
Top